FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food...

Related Keywords

Canada ,Japan ,Tokyo ,United States ,America ,American ,Chris Boshoff ,Ahsan Arozullah ,Naoki Okamura ,Prnewswire Pfizer Inc ,Astellas Inc ,Exchange Commission ,Head Of Oncology Development ,Astellas Pharma Inc ,European Union ,American Society Of Clinical Oncology ,Drug Administration ,Oncology Research ,Pfizer ,Lab Abnormalities ,Medivation Inc ,Astellas Pharma ,Priority Review ,New Drug Application ,Prescription Drug User Fee Act ,Chief Oncology Research ,Development Officer ,Executive Vice President ,Senior Vice President ,Oncology Development ,Hazard Ratio ,Confidence Interval ,Pfizer Led Phase ,South America ,High Risk Biochemical ,Reversible Encephalopathy Syndrome ,Heart Disease ,Fetal Toxicity ,Drug Interactions ,Full Prescribing Information ,Pfizer Oncology ,Focus Area Approach ,Annual Report ,Looking Information ,Factors That May Affect Future ,Accessed March ,Prostate Cancer ,Clin Pract ,North America ,